Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1988 1
1990 1
1999 4
2000 2
2001 1
2002 1
2003 3
2004 3
2005 2
2006 5
2007 3
2008 3
2009 3
2010 6
2011 4
2012 6
2013 6
2014 7
2015 7
2016 5
2017 12
2018 6
2019 7
2020 8
2021 11
2022 3
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Gastroesophageal Junction Adenocarcinoma"
Page 1
Current treatment and recent progress in gastric cancer.
Joshi SS, Badgwell BD. Joshi SS, et al. CA Cancer J Clin. 2021 May;71(3):264-279. doi: 10.3322/caac.21657. Epub 2021 Feb 16. CA Cancer J Clin. 2021. PMID: 33592120 Free PMC article. Review.
Systemic chemotherapy, radiotherapy, surgery, immunotherapy, and targeted therapy all have proven efficacy in gastric adenocarcinoma; therefore, multidisciplinary treatment is paramount to treatment selection. ...Significant research opportunities remain for the less diffe …
Systemic chemotherapy, radiotherapy, surgery, immunotherapy, and targeted therapy all have proven efficacy in gastric adenocarcinoma; …
Gastric cancer.
Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Van Cutsem E, et al. Lancet. 2016 Nov 26;388(10060):2654-2664. doi: 10.1016/S0140-6736(16)30354-3. Epub 2016 May 5. Lancet. 2016. PMID: 27156933 Review.
Many patients have inoperable disease at diagnosis or have recurrent disease after resection with curative intent. Gastric cancer is separated anatomically into true gastric adenocarcinomas and gastro-oesophageal-junction adenocarcinomas, and histologi …
Many patients have inoperable disease at diagnosis or have recurrent disease after resection with curative intent. Gastric cancer is …
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Ajani JA, D'Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Farjah F, Gerdes H, Gibson M, Grierson P, Hofstetter WL, Ilson DH, Jalal S, Keswani RN, Kim S, Kleinberg LR, Klempner S, Lacy J, Licciardi F, Ly QP, Matkowskyj KA, McNamara M, Miller A, Mukherjee S, Mulcahy MF, Outlaw D, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian NR, Pluchino LA. Ajani JA, et al. J Natl Compr Canc Netw. 2023 Apr;21(4):393-422. doi: 10.6004/jnccn.2023.0019. J Natl Compr Canc Netw. 2023. PMID: 37015332
Cancers originating in the esophagus or esophagogastric junction constitute a major global health problem. Esophageal cancers are histologically classified as squamous cell carcinoma (SCC) or adenocarcinoma, which differ in their etiology, pathology, tumor lo …
Cancers originating in the esophagus or esophagogastric junction constitute a major global health problem. Esophageal cancers …
Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
Weusten BLAM, Bisschops R, Dinis-Ribeiro M, di Pietro M, Pech O, Spaander MCW, Baldaque-Silva F, Barret M, Coron E, Fernández-Esparrach G, Fitzgerald RC, Jansen M, Jovani M, Marques-de-Sa I, Rattan A, Tan WK, Verheij EPD, Zellenrath PA, Triantafyllou K, Pouw RE. Weusten BLAM, et al. Endoscopy. 2023 Dec;55(12):1124-1146. doi: 10.1055/a-2176-2440. Epub 2023 Oct 9. Endoscopy. 2023. PMID: 37813356 Free article.
MR1 : ESGE recommends the following standards for Barrett esophagus (BE) surveillance:- a minimum of 1-minute inspection time per cm of BE length during a surveillance endoscopy- photodocumentation of landmarks, the BE segment including one picture per cm of BE length, and the …
MR1 : ESGE recommends the following standards for Barrett esophagus (BE) surveillance:- a minimum of 1-minute inspection time per cm of BE l …
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.
Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, Mamon HJ, Moehler M, Fu X, Cho BC, Bordia S, Bhagia P, Shih CS, Desai A, Enzinger P. Shah MA, et al. Future Oncol. 2021 Apr;17(10):1143-1153. doi: 10.2217/fon-2020-0969. Epub 2021 Feb 3. Future Oncol. 2021. PMID: 33533655 Free PMC article. Clinical Trial.
Pembrolizumab is well tolerated and provides promising antitumor activity in patients with previously treated, advanced, unresectable esophageal/esophagogastric junction cancer. Combining pembrolizumab with chemoradiotherapy may further improve outcomes in the first …
Pembrolizumab is well tolerated and provides promising antitumor activity in patients with previously treated, advanced, unresectable esopha …
AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus With Dysplasia and/or Early Cancer: Expert Review.
Sharma P, Shaheen NJ, Katzka D, Bergman JJGHM. Sharma P, et al. Gastroenterology. 2020 Feb;158(3):760-769. doi: 10.1053/j.gastro.2019.09.051. Epub 2019 Nov 12. Gastroenterology. 2020. PMID: 31730766 Review.
BEST PRACTICE ADVICE 4: BET should be preferred over esophagectomy for BE patients with intramucosal esophageal adenocarcinoma (T1a). BEST PRACTICE ADVICE 5: BET is a reasonable alternative to esophagectomy in patients with submucosal esophageal adenocarcinoma (T1b) …
BEST PRACTICE ADVICE 4: BET should be preferred over esophagectomy for BE patients with intramucosal esophageal adenocarcinoma (T1a). …
Adenocarcinoma of the esophagus: controversies and consensus.
Ilson DH. Ilson DH. Chin Clin Oncol. 2017 Oct;6(5):52. doi: 10.21037/cco.2017.09.02. Chin Clin Oncol. 2017. PMID: 29129092 Free article. Review.
Esophageal cancer, the sixth most common cause of cancer globally, is characterized by the development of early systemic metastatic disease. Adenocarcinoma of the esophagus and gastroesophageal junction (GEJ) is more common in the West. Preoperative chemother …
Esophageal cancer, the sixth most common cause of cancer globally, is characterized by the development of early systemic metastatic disease. …
Approach to the Post-Ablation Barrett's Esophagus Patient.
Kahn A, Shaheen NJ, Iyer PG. Kahn A, et al. Am J Gastroenterol. 2020 Jun;115(6):823-831. doi: 10.14309/ajg.0000000000000514. Am J Gastroenterol. 2020. PMID: 31899706 Review.
Most recurrences occur at the gastroesophageal junction, whereas those in the tubular esophagus are endoscopically visible and distally located. A simplified biopsy protocol limited to the distal aspect of the BE segment, in addition to gastroesophageal …
Most recurrences occur at the gastroesophageal junction, whereas those in the tubular esophagus are endoscopically visi …
Diagnosis and treatment of non-metastatic esophagogastric junction adenocarcinoma: what are the current options?
Gronnier C, Piessen G, Mariette C. Gronnier C, et al. J Visc Surg. 2012 Feb;149(1):e23-33. doi: 10.1016/j.jviscsurg.2012.01.003. Epub 2012 Feb 16. J Visc Surg. 2012. PMID: 22341763 Free article. Review.
While the prevalence of distal gastric cancer is decreasing in the western world, there has been an alarming rise in the incidence of esophagogastric junction adenocarcinoma (EGJA) during recent decades. ...Therapy strategies are complex due to the anatomical …
While the prevalence of distal gastric cancer is decreasing in the western world, there has been an alarming rise in the incidence of eso …
Recurrence after surgery in esophago-gastric junction adenocarcinoma: Current management and future perspectives.
Neri A, Marrelli D, Voglino C, Di Mare G, Ferrara F, Marini M, Roviello F. Neri A, et al. Surg Oncol. 2016 Dec;25(4):355-363. doi: 10.1016/j.suronc.2016.08.003. Epub 2016 Aug 16. Surg Oncol. 2016. PMID: 27916166 Review.
Recurrent esophago-gastric junction adenocarcinoma is not a rare event and its correct management is still debated. ...The aim of this review is to investigate the different rates, patterns and timings of recurrence of this tumor, and to explain the va …
Recurrent esophago-gastric junction adenocarcinoma is not a rare event and its correct management is still debated. ... …
112 results